PMID- 26618548 OWN - NLM STAT- MEDLINE DCOM- 20161213 LR - 20181113 IS - 1476-5365 (Electronic) IS - 0268-3369 (Linking) VI - 51 IP - 3 DP - 2016 Mar TI - Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. PG - 351-7 LID - 10.1038/bmt.2015.278 [doi] AB - Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data specific to adult T-ALL have been described thus far. Specifically, the optimal myeloablative conditioning regimen is unknown. In this retrospective study, 601 patients were included. Patients received allo-SCT in CR1, CR2, CR >2 or in advanced disease in 69%, 15%, 2% and 14% of cases, respectively. With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan-cyclophosphamide (IV Bu-Cy) (n=46). Unlike patients aged ⩾35 years, patients aged <35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen (5-year leukemia-free survival (LFS) of 50% for TBI versus 18% for chemo-only regimen or IV Bu-Cy regimens, P=10(-5) and 10(-4), respectively). In multivariate analysis, use of TBI was associated with an improved LFS (hazard ratio (HR)=0.55 (0.34-0.86), P=0.01) and overall survival (HR=0.54 (0.34-0.87), P=0.01) in patients aged <35 years. In conclusion, younger adult patients with T-ALL entitled to receive a myeloablative allo-SCT may benefit from TBI-based regimens. FAU - Cahu, X AU - Cahu X AD - Hematologie Clinique, Hopital Pontchaillou, CHU Rennes, France. FAU - Labopin, M AU - Labopin M AD - Service d'Hematologie Clinique et Therapie Cellulaire, Hopital Saint-Antoine, AP-HP, Paris, France. AD - Universite Pierre and Marie Curie, Paris, France. AD - INSERM, UMR_S 938, INSERM, Paris, France. FAU - Giebel, S AU - Giebel S AD - Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland. FAU - Aljurf, M AU - Aljurf M AD - Adult Hematology/HSCT, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Kyrcz-Krzemien, S AU - Kyrcz-Krzemien S AD - Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland. FAU - Socie, G AU - Socie G AD - Hematology-Transplantation, Hospital St Louis, APHP, Paris, France. FAU - Eder, M AU - Eder M AD - Hannover Medical School, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany. FAU - Bonifazi, F AU - Bonifazi F AD - Institute of Hematology, Department of Hematology and Oncological Sciences 'L. and A. Seragnoli,' University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. FAU - Bunjes, D AU - Bunjes D AD - Klinik fur Innere Medizin III, Universitatsklinikum Ulm, Germany. FAU - Vigouroux, S AU - Vigouroux S AD - Hematologie Clinique et Therapie Cellulaire, Hopital Haut Leveque, Pessac, France. FAU - Michallet, M AU - Michallet M AD - Hematologie Clinique, Hospices Civils de Lyon, Lyon, France. FAU - Stelljes, M AU - Stelljes M AD - Department of Medicine A/Hematology and Oncology, University of Muenster Muenster, Germany. FAU - Zuckerman, T AU - Zuckerman T AD - Department of Hematology and Bone Marrow Transplantation, Rambam MCH, Haifa, Israel. FAU - Finke, J AU - Finke J AD - Department of Medecine-Hematology, Oncology, University of Freiburg, Freiburg, Germany. FAU - Passweg, J AU - Passweg J AD - Hematology, University Hospital of Basel, Basel, Switzerland. FAU - Yakoub-Agha, I AU - Yakoub-Agha I AD - Hematologie Clinique, Hopital Claude Huriez, Lille, France. FAU - Niederwieser, D AU - Niederwieser D AD - University Hospital Leipzig, Clinic for Hematology and Oncology, Leipzig, Germany. FAU - Sucak, G AU - Sucak G AD - Department of Hematology, Gazi University Faculty of Medicine, Ankara, Turkey. FAU - Sengelov, H AU - Sengelov H AD - National University Hospital, Copenhagen, Denmark. FAU - Polge, E AU - Polge E AD - Service d'Hematologie Clinique et Therapie Cellulaire, Hopital Saint-Antoine, AP-HP, Paris, France. AD - Universite Pierre and Marie Curie, Paris, France. AD - INSERM, UMR_S 938, INSERM, Paris, France. FAU - Nagler, A AU - Nagler A AD - Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel. FAU - Esteve, J AU - Esteve J AD - Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain. FAU - Mohty, M AU - Mohty M AD - Service d'Hematologie Clinique et Therapie Cellulaire, Hopital Saint-Antoine, AP-HP, Paris, France. AD - Universite Pierre and Marie Curie, Paris, France. AD - INSERM, UMR_S 938, INSERM, Paris, France. CN - Acute Leukemia Working Party of EBMT LA - eng PT - Comparative Study PT - Journal Article DEP - 20151130 PL - England TA - Bone Marrow Transplant JT - Bone marrow transplantation JID - 8702459 RN - 8N3DW7272P (Cyclophosphamide) RN - G1LN9045DK (Busulfan) SB - IM MH - Adult MH - Busulfan/*administration & dosage MH - Cyclophosphamide/*administration & dosage MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - *Hematopoietic Stem Cell Transplantation MH - Humans MH - Male MH - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/mortality/therapy MH - *Registries MH - Survival Rate MH - Transplantation Conditioning/*methods MH - *Whole-Body Irradiation EDAT- 2015/12/01 06:00 MHDA- 2016/12/15 06:00 CRDT- 2015/12/01 06:00 PHST- 2015/04/14 00:00 [received] PHST- 2015/08/15 00:00 [revised] PHST- 2015/09/14 00:00 [accepted] PHST- 2015/12/01 06:00 [entrez] PHST- 2015/12/01 06:00 [pubmed] PHST- 2016/12/15 06:00 [medline] AID - bmt2015278 [pii] AID - 10.1038/bmt.2015.278 [doi] PST - ppublish SO - Bone Marrow Transplant. 2016 Mar;51(3):351-7. doi: 10.1038/bmt.2015.278. Epub 2015 Nov 30.